Serum uric acid and clinical progression in parkinson disease: Potential biomarker for nigrostriatal failure

Archives of Neurology

Volumn 65, Issue 6, 2008, Pages 698-699

  Schiess, Mya ^a   Oh, Irene ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SYNUCLEIN; BIOLOGICAL MARKER; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; URIC ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; BODY MASS; BRAIN CORTEX; BRAIN STEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; EDITORIAL; FEMALE; GENE MUTATION; HEREDITY; HUMAN; KIDNEY FUNCTION; LEWY BODY; LIGAND BINDING; LONGITUDINAL STUDY; MALE; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; CORPUS STRIATUM; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANTIA NIGRA; URIC ACID;

EID: 45149089053     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.6.698     Document Type: Editorial

References (13)

1. Suchowersky O, Riech S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: Diagnosis and prognosis of new-onset Parkinson disease (an evidence-based review). Neurology. 2006;66(7):968-975.
2. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease; a population based study. Neurology. 2005;65(9):1436-1441.
3. Schwarzschild MA, Schwid SR, Marek K, et al; Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-723.
4. Braak H, Del Tredici K, Rob U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
5. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46(10):1052-1060.
6. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611-1615.
7. Post B, Merkus MP, de Haan RJ, Speelman JD. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord. 2007;22 (13):1839-1851.
8. McDermott MP, Jankovic J, Carter J; Parkinson Study Group. Factors predictive of the need for levodopa therapy in early untreated Parkinson's disease. Arch Neurol. 1995;52(6):565-570.
9. de Lau LM, Koudstaal PJ, Hofman A, Breteler MMB. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58(5):797-800.
10. Davis JW, Grandietti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol. 1996;144(5):480-484.
11. Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69(14):1418- 1423.
12. Ruggiero C, Cherubini A, Ble A, et al. Uric acid and inflammatory markers. Eur Heart J. 2006;27(10):1174-1181.
13. Wahner AD, Bronstein JF, Bordelon YM, Ritz B. Non-steroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 2007;69(19):1836-1842.